Search Result
Results for "
DHODH inhibitor
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0083
-
-
-
- HY-108325
-
-
-
- HY-112645
-
-
-
- HY-104029
-
|
F901318
|
Fungal
Dihydroorotate Dehydrogenase
|
Infection
|
|
Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp. .
|
-
-
- HY-124593
-
PTC299
5 Publications Verification
Emvododstat
|
VEGFR
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Cancer
|
|
PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies .
|
-
-
- HY-15510
-
|
|
MDM-2/p53
Dihydroorotate Dehydrogenase
Sirtuin
Autophagy
|
Cancer
|
|
Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH) .
|
-
-
- HY-129239
-
|
ASLAN003
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Farudodstat (ASLAN003) is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. Farudodstat inhibits protein synthesis via activation of AP-1 transcription factors. Farudodstat induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice .
|
-
-
- HY-14908
-
|
4sc-101; SC12267
|
Dihydroorotate Dehydrogenase
Interleukin Related
FXR
|
Infection
Inflammation/Immunology
|
|
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver by targeting FXR .
|
-
-
- HY-152851
-
|
IMU-935
|
ROR
Dihydroorotate Dehydrogenase
SARS-CoV
CMV
|
Infection
|
|
Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties .
|
-
-
- HY-N6961
-
|
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
|
-
-
- HY-148396
-
|
|
DNA/RNA Synthesis
|
Infection
Cancer
|
|
UCK2 Inhibitor-3 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2, a pyrimidine salvage enzyme) with an IC50 value of 16.6 μM. UCK2 can replace dihydroorotate dehydrogenase (DHODH), in a certain extent, in infected or rapidly dividing cells to continue efficient uridine salvage. UCK2 Inhibitor-3 also inhibits DNA polymerase eta and kappa with IC50s of 56 μM and 16 μM .
|
-
-
- HY-148394
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
UCK2 Inhibitor-1 (Compound 20874830-2) is a non-competitive UCK2 inhibitor with an IC50 of 4.7 μM. UCK2 Inhibitor-1 acts as a non-competitive inhibitor against uridine and ATP, and functionally inhibits the enzymatic activity of UCK2. UCK2 Inhibitor-1 suppresses the uridine salvage pathway. UCK2 Inhibitor-1 can be used in chronic myeloid leukemia research .
|
-
-
- HY-N3097
-
-
-
- HY-139189
-
-
-
- HY-100688
-
ML390
1 Publications Verification
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .
|
-
-
- HY-13423
-
|
|
MDM-2/p53
Dihydroorotate Dehydrogenase
Sirtuin
Autophagy
|
Cancer
|
|
Tenovin-1, a p53 activator, protects p53 from MDM2-mediated degradation. Tenovin-1 acts through inhibition of the protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also a dihydroorotate dehydrogenase (DHODH) inhibitor .
|
-
-
- HY-137463
-
-
-
- HY-15510B
-
|
|
MDM-2/p53
Dihydroorotate Dehydrogenase
Sirtuin
Autophagy
|
Cancer
|
|
Tenovin-6 Hydrochloride, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 Hydrochloride inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 Hydrochloride also inhibits dihydroorotate dehydrogenase (DHODH) .
|
-
-
- HY-135282
-
-
-
- HY-101813
-
|
HR325
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .
|
-
-
- HY-153112
-
-
-
- HY-128787
-
-
-
- HY-132174
-
|
|
Flavivirus
Dengue Virus
CHIKV
Dihydroorotate Dehydrogenase
|
Infection
|
|
CHIKV-IN-2 is a potent inhibitor against Chikungunya virus (CHIKV), with excellent cellular antiviral activity (EC90=270 nM) and improved liver microsomal stability. CHIKV-IN-2 shows inhibitory activity against a cellular target Dihydroorotate Dehydrogenase (DHODH), which interacts with various viruses and regulate their replication via depleting intracellular pyrimidine pools .
|
-
-
- HY-142834
-
-
-
- HY-135678
-
-
-
- HY-135664
-
-
-
- HY-128068
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC50=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML) .
|
-
-
- HY-132170
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
DSM502 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM502 exhibits nanomolar potency againsts Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs .
|
-
-
- HY-132171A
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
DSM705 hydrochloride, an orally active antimalarial compound, is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 hydrochloride exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites (IC50=95, 52 nM for P. falciparum and P. vivax DHODH, respectively), with no inhibition of mammalian DHODHs .
|
-
-
- HY-135619
-
-
-
- HY-B0083S
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
Leflunomide-d4 (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent .
|
-
-
- HY-32757
-
|
5-Bromo-2-fluoro-3-picoline
|
Drug Intermediate
|
Others
|
|
5-Bromo-2-fluoro-3-methylpyridine (5-Bromo-2-fluoro-3-picoline) is a drug synthesis intermediate that can be used to synthesize an inhibitor of dihydroorotate dehydrogenase (DHODH) .
|
-
-
- HY-144169
-
|
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Inflammation/Immunology
Cancer
|
|
DHODH-IN-19 is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-19 inhibits tumor growth. DHODH-IN-19 has the potential for the research of cancer and inflammation disease (extracted from patent WO2021238881A1, compound 1) .
|
-
-
- HY-178156
-
|
|
Dihydroorotate Dehydrogenase
SARS-CoV
|
Infection
|
|
DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2 .
|
-
-
- HY-132171
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
DSM705 is a pyrrole-based Dihydroorotate Dehydrogenase (DHODH) inhibitor. DSM705 exhibits nanomolar potency against Plasmodium DHODH and Plasmodium parasites, with no inhibition of mammalian DHODHs. DSM705 is a potent antimalarial compound .
|
-
-
- HY-178941
-
|
|
Dihydroorotate Dehydrogenase
Apoptosis
Caspase
Reactive Oxygen Species (ROS)
|
Cancer
|
|
DHODH-IN-32 (Compound A1) is a DHODH inhibitor. DHODH-IN-32 shows significant cytotoxicity against NCI-60 cell lines, especially being sensitive to breast cancer, prostate cancer and leukemia cell lines. DHODH-IN-32 can induce cell apoptosis by activating the Caspase pathway. DHODH-IN-32 causes G0/G1 phase cell cycle arrest and inhibits cellular metabolism by ROS. DHODH-IN-32 exhibits significant anti-tumor properties in mouse breast cancer models. DHODH-IN-32 can be used for the study of breast cancer .
|
-
-
- HY-135675
-
-
-
- HY-135666
-
-
-
- HY-135667
-
-
-
- HY-108325R
-
-
-
- HY-N6961R
-
|
|
Reference Standards
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Parasite
|
Infection
Inflammation/Immunology
Cancer
|
|
Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
|
-
-
- HY-120924
-
-
-
- HY-14908A
-
|
4sc-101 hemicalcium; SC12267 hemicalcium
|
Dihydroorotate Dehydrogenase
Interleukin Related
FXR
|
Infection
Inflammation/Immunology
|
|
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR .
|
-
-
- HY-176728
-
|
|
Dihydroorotate Dehydrogenase
|
Infection
|
|
DHODH-IN-27 (WF-8) is a dihydroacetate dehydrogenase (DHODH) inhibitor with an IC50 of 64.97 μM. DHODH-IN-27 can be used as an anti-DHODH herbicide .
|
-
-
- HY-175423
-
|
|
Dihydroorotate Dehydrogenase
|
Metabolic Disease
|
|
DHODH-IN-30 (compound 4g) is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC50 of 32 nM. DHODH-IN-30 exhibits protective effects against oxidative stress .
|
-
-
- HY-169220S
-
-
-
- HY-149030
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML) .
|
-
-
- HY-144371
-
-
-
- HY-135677
-
-
-
- HY-135679
-
-
- HY-139889
-
-
- HY-163328
-
|
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Cancer
|
|
DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML) .
|
-
- HY-135618
-
|
|
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
|
Infection
|
|
DHODH-IN-3 (compound 3) is a potent inhibitor of Human Dihydroorotate Dehydrogenases (HsDHODH) with an IC50 value of 261 nM. DHODH-IN-3 binds to the the ubiquinone binding cavities in DHODH with a Ki app of 32 nM. DHODH-IN-3 has the potential for malaria treatment .
|
-
- HY-163158
-
-
- HY-149031
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
DHODH-IN-22 is a potent, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 0.3 nM. DHODH-IN-22 can be used for researching acute myelogenous leukemia (AML) .
|
-
- HY-158023
-
-
- HY-135676
-
-
- HY-174816
-
|
|
Fluorescent Dye
Dihydroorotate Dehydrogenase
|
Infection
Cancer
|
|
DHODH-IN-28 (Compound 11a) is a potent fluorescent inhibitor targeting human dihydroorotate dehydrogenase (hDHODH) with an IC50 value of 170 nM. DHODH-IN-28 exhibits antileukemic and antiviral activities. DHODH-IN-28 is promising for research of cancers and infectious diseases .
|
-
- HY-142847
-
-
- HY-142843
-
|
|
ROR
Dihydroorotate Dehydrogenase
|
Inflammation/Immunology
|
|
RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC50s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity .
|
-
- HY-175259
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
DHODH-IN-29 (Compound 2i) is a covalent inhibitor of Leishmania braziliensis Dihydroorotate Dehydrogenase (LbDHODH) with an IC50 value of 0.5 μM. DHODH-IN-29 is promising for research of antileishmaniasis .
|
-
- HY-169222S
-
|
|
Dihydroorotate Dehydrogenase
ROR
SARS-CoV
|
Infection
|
|
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .
|
-
- HY-139825
-
-
- HY-146317
-
-
- HY-149877
-
|
|
DNA/RNA Synthesis
Dihydroorotate Dehydrogenase
|
Cancer
|
|
hDHODH-IN-12 is a potent DHODH inhibitor with an IC50 value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer .
|
-
- HY-129253
-
|
|
HPV
|
Infection
|
|
GSK984 is an inactive control probe for GSK983 (HY-119098), a dihydroorotate dehydrogenase (DHODH) inhibitor with antiviral activity .
|
-
- HY-108325S
-
-
- HY-B0083R
-
|
HWA486 (Standard); RS-34821 (Standard); SU101 (Standard)
|
Reference Standards
Dihydroorotate Dehydrogenase
Endogenous Metabolite
Bacterial
|
Cancer
|
|
Leflunomide (Standard) is the analytical standard of Leflunomide. This product is intended for research and analytical applications. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
|
-
- HY-B0083S1
-
-
- HY-101813R
-
|
HR325 (Standard)
|
Reference Standards
Dihydroorotate Dehydrogenase
DNA/RNA Synthesis
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Laflunimus (Standard) is the analytical standard of Laflunimus. This product is intended for research and analytical applications. Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 μM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor .
|
-
- HY-120462
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
Genz-669178 is an inhibitor for dihydroorotate dehydrogenase (DHODH) with IC50 of 0.015-0.05 μM in Plasmodium spp.. Genz-669178 inhibits P. berghei, P. falciparum strains 3D7 and Dd2 with IC50 of 0.068, 0.008 and 0.01 μM, respectively. Genz-669178 exhibits anti-malarial efficacy in P. berghei-infected mice with ED50 of 13-21 mg/kg/day. Genz-669178 exhibits good pharmacokinetic characteristics in mice .
|
-
- HY-N3097R
-
-
- HY-135662
-
|
|
Dihydroorotate Dehydrogenase
|
Infection
|
|
DHODH-IN-34 (Compound 21q) is a potent human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 13 nM. DHODH-IN-34 is promising for research of RNA viruses such as measles virus and chikungunya virus .
|
-
- HY-179531
-
|
|
Autophagy
Ferroptosis
ROS Kinase
|
Cancer
|
|
DHODH-IN-33 is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with potent activity against A549 (IC50 = 5.22 μM) and 5637 (IC50 = 3.03 μM). DHODH-IN-33 induces autophagy-dependent ferroptosis (mitochondrial dysfunction, lipid peroxidation, and ROS accumulation) with no notable toxicity in vivo. DHODH-IN-33 exerts anti-cancer effect by promoting the autophagy-dependent degradation of DHODH. DHODH-IN-33 can be used for non-small cell lung cancer and bladder cancer .
|
-
- HY-182550
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
Indoluidin D is a selective dihydroorotate dehydrogenase (DHODH) inhibitor with a human DHODH IC50 of 210 nM. Indoluidin D selectively inhibits human DHODH activity, with induced effects rescuable by orotic acid. Indoluidin D promotes myeloid differentiation and inhibits cancer cell proliferation. Indoluidin D can be used for the research of acute promyelocytic leukemia .
|
-
- HY-117908
-
|
|
Dihydroorotate Dehydrogenase
Parasite
|
Infection
|
|
DSM267 is a triazolopyrimidine inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH), with an IC50 of 38 nM, while its IC50 against human DHODH exceeds 100000 nM. DSM267 is used for the in vitro systematic screening and characterization of the resistance evolution pathways of Plasmodium falciparum to DHODH inhibitors .
|
-
- HY-170780A
-
|
|
Dihydroorotate Dehydrogenase
|
Infection
|
|
(S)-DSM1465 is a Plasmodium dihydroorotate dehydrogenase (DHODH) inhibitor. (S)-DSM1465 exhibits potential inhibitory activity against Plasmodium falciparum and Plasmodium vivax, and can be used in malaria research .
|
-
- HY-104029R
-
|
F901318 (Standard)
|
Fungal
Reference Standards
Dihydroorotate Dehydrogenase
|
Infection
|
|
Olorofim (Standard) is the analytical standard of Olorofim (HY-104029). This product is intended for research and analytical applications. Olorofim (F901318) selectively inhibits fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the pyrimidine biosynthesis pathway. Olorofim (F901318). Olorofim exhibits excellent activity against A. fumigatus and other Aspergillus spp. .
|
-
- HY-100688R
-
|
|
Reference Standards
Dihydroorotate Dehydrogenase
|
Cancer
|
|
ML390 (Standard) is the analytical standard of ML390 (HY-100688). This product is intended for research and analytical applications. ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .
|
-
- HY-15510S
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Tenovin-6-d6 is the deuterium labeled Tenovin-6 (HY-15510). Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH).
|
-
- HY-183925
-
|
|
HIV
Dihydroorotate Dehydrogenase
|
Infection
|
|
Redoxal is a dihydroorotate dehydrogenase (DHODH) inhibitor and anti-HIV-1 agent. Redoxal induces intracellular pyrimidine depletion by inhibiting the de novo pyrimidine biosynthesis pathway, enhances the protein stability of APOBEC3G (A3G), upregulates the abundance of A3G protein in cells and progeny viral particles, thereby strengthening the host endogenous antiviral restriction mediated by A3G . Redoxal selectively targets DHOdehase at the mitochondrial level, with an IC50 of 430 nM for inhibiting DHO oxidation in human mitochondria and an IC50 of 910 nM in rat mitochondria . Redoxal can be used in studies related to HIV-1 infection .
|
-
- HY-181588
-
|
|
Nuclear Hormone Receptor 4A/NR4A
|
Neurological Disease
Inflammation/Immunology
|
|
NR4A agonist-2 is a selective pan-NR4A agonist designed based on Vidofludimus (HY-14908), with a Kd of 0.10 μM against NR4A1, and EC50 values of 0.098 μM, 0.092 μM and 0.09 μM against Nur77, Nurr1, NOR-1, respectively. NR4A agonist-2 exhibits 47-fold selectivity over DHODH, and shows no cytotoxic activity at concentrations up to 10 μM. By binding to a specific surface pocket in the ligand-binding domain of Nurr1, NR4A agonist-2 inhibits the formation of Nurr1 homodimers, activates response elements such as NBRE, NurRE, DR5, and then potently induces the expression of neuroprotective genes including BDNF, SOD2, thereby exerting neuroprotective activity. NR4A agonist-2 can be used in the research of neurodegenerative diseases such as Parkinson's disease, dementia and multiple sclerosis .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-32757
-
|
5-Bromo-2-fluoro-3-picoline
|
Biochemical Assay Reagents
|
|
5-Bromo-2-fluoro-3-methylpyridine (5-Bromo-2-fluoro-3-picoline) is a drug synthesis intermediate that can be used to synthesize an inhibitor of dihydroorotate dehydrogenase (DHODH) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0083S
-
|
|
|
Leflunomide-d4 (HWA486-d4) is the deuterium labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent .
|
-
-
- HY-169220S
-
|
|
|
RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC50 values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .
|
-
-
- HY-169222S
-
|
|
|
RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .
|
-
-
- HY-108325S
-
|
|
|
Brequinar-d3 (DUP785-d3) is deuterium labeled Brequinar. Brequinar (DUP785) is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 of 5.2 nM for human DHODH. Brequinar has potent activities against a broad spectrum of viruses. Brequinar also has an anti-SARS2 activity .
|
-
-
- HY-B0083S1
-
|
|
|
Leflunomide- 13C6 (HWA486- 13C6) is 13C labeled Leflunomide. Leflunomide is a pyrimidine synthesis inhibitor, inhibiting dihydroorotate dehydrogenase (DHODH), and acts as a disease-modifying antirheumatic agent.
|
-
-
- HY-15510S
-
|
|
|
Tenovin-6-d6 is the deuterium labeled Tenovin-6 (HY-15510). Tenovin-6, an analog of Tenovin-1 (HY-13423), is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH).
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: